Listed
Stock Code: 334970
| Company Name | 프레스티지바이오로직스(주) |
| English Name | Prestige Biologics Co., Ltd. |
| Business Reg. No. | 7778600083 |
| CEO | 김진우 |
| Address | 충청북도 청주시 흥덕구 오송읍 오송생명1로 197 |
| Industry | 생물 의약품 제조업 |
| Industry Code | 212 |
| Main Products | 바이오시밀러 제조,도소매/생명공학연구,개발,생명과학기술제공 |
| Established | 2015-06-02 |
| Phone | 043-232-1552 |
| Website | www.prestigebiologics.com |
| Regular Employees | 279persons |
| Corp. Reg. No. | 1101115739804 |
Venture Certified
| 기술평가보증기업(기금) | 2017-08-24 ~ 2019-08-23 | 20170109901 | 2017-08-24 |
| 연구개발유형 | 2019-08-24 ~ 2021-08-23 | 20190110939 | 2017-08-24 |
| 연구개발유형 | 2021-08-24 ~ 2024-08-23 | 20211013020030 | 2017-08-24 |
| 연구개발유형 | 2024-12-04 ~ 2027-12-03 | 20241204020009 | 2017-08-24 |
Revenue CAGR -12.4%
| Item | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 21.7B | 17.3B | 0.2B | 32.3B |
| Operating Profit | -334.3B | -221.1B | -366.3B | -268.4B |
| Net Profit | -293.7B | -179.8B | 497.2B | -393.8B |
| Total Assets | 2894.1B | 3057.5B | 2580.8B | 2067.7B |
| Total Liabilities | 2177.3B | 2059.5B | 1404.7B | 999.4B |
| Total Equity | 716.8B | 998.0B | 1176.1B | 1068.3B |
Operating Loss: Op. profit -334B
2 Consecutive Years of Net Loss
Debt Ratio Surge (+97pp YoY)
▲ 30.9%
▼ 17.2%
▲ 98.1%
▲ 117.3%
▼ 875.5%
| Name | Position | Role | Comp. (M KRW) |
|---|---|---|---|
| 김진우 | 사내이사 | 경영총괄 | - |
| 양재영 | 사내이사 | B.D.센터 자문역 | - |
| 임영수 | 사내이사 | CFO/ 경영지원본부 총괄 | - |
| 현덕훈 | 미등기 | 경영총괄 | - |
| 정진섭 | 사외이사 | - | - |
| 배기수 | 사외이사 | - | - |
| 안영욱 | 사외이사 | - | - |
| 동현철 | 기타비상무이사 | - | - |
| Tan Ting Yong | 기타비상무이사 | - | - |
| Shareholder | Ownership (%) | Shares Held |
|---|---|---|
| - | ||
| - | ||
| - |
| Regular Employees | 279persons |
| CEO | 김진우 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "충북 청주시",
"ceo_name": "KIM MICHAEL JINWOO (김진우)",
"certificate": [
{
"cert_number": "20170109901",
"changes": "",
"disclosure_date": "2017-08-24",
"first_cert_date": "2017-08-24",
"no": "1",
"type": "기술평가보증기업(기금)",
"valid_period": "2017-08-24 ~ 2019-08-23"
},
{
"cert_number": "20190110939",
"changes": "",
"disclosure_date": "2019-09-20",
"first_cert_date": "2017-08-24",
"no": "2",
"type": "연구개발유형",
"valid_period": "2019-08-24 ~ 2021-08-23"
},
{
"cert_number": "20211013020030",
"changes": "",
"disclosure_date": "2021-10-13",
"first_cert_date": "2017-08-24",
"no": "3",
"type": "연구개발유형",
"valid_period": "2021-08-24 ~ 2024-08-23"
},
{
"cert_number": "20241204020009",
"changes": "대표자",
"disclosure_date": "2024-12-04",
"first_cert_date": "2017-08-24",
"no": "4",
"type": "연구개발유형",
"valid_period": "2024-12-04 ~ 2027-12-03"
}
],
"company_name": "프레스티지바이오로직스 주식회사",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 30553985000,
"cost_of_sales": 11965000,
"current_assets": 29835242000,
"current_liabilities": 32551654000,
"gross_profit": 3601000,
"net_income": -49717905000,
"net_income_bs": -49717904000,
"non_current_assets": 228243994000,
"non_current_liabilities": 107916230000,
"non_operating_expenses": 19906641000,
"non_operating_income": 6819989000,
"operating_profit": -36631253000,
"revenue": 15566000,
"sga_expenses": 36634854000,
"total_assets": 258079236000,
"total_equity": 117611351000,
"total_liabilities": 140467885000
},
"2023": {
"capital_stock": 30553985000,
"cost_of_sales": 1212667000,
"current_assets": 70242172000,
"current_liabilities": 89097644000,
"gross_profit": 517597000,
"net_income": -17979639000,
"net_income_bs": -17979639000,
"non_current_assets": 235510872000,
"non_current_liabilities": 116852624000,
"non_operating_expenses": 6516656000,
"non_operating_income": 10642280000,
"operating_profit": -22105263000,
"revenue": 1730264000,
"sga_expenses": 22622860000,
"total_assets": 305753043000,
"total_equity": 99802775000,
"total_liabilities": 205950268000
},
"2024": {
"capital_stock": 30750735000,
"cost_of_sales": 10855571000,
"current_assets": 55635526000,
"current_liabilities": 92305793000,
"gross_profit": -8686529000,
"net_income": -29373786000,
"net_income_bs": -29373786000,
"non_current_assets": 233778535000,
"non_current_liabilities": 125426146000,
"non_operating_expenses": 26118554000,
"non_operating_income": 30174753000,
"operating_profit": -33429985000,
"revenue": 2169042000,
"sga_expenses": 24743456000,
"total_assets": 289414061000,
"total_equity": 71682122000,
"total_liabilities": 217731939000
}
},
"industry": "생물 의약품 제조업",
"investment": [],
"main_products": "바이오시밀러 제조,도소매/생명공학연구,개발,생명과학기술제공",
"phone": "043-232-****",
"years": [
2024,
2023,
2022
]
}